antimicrobi
stewardship
role
microbiolog
laboratori
infecti
diseas
diagnosi
rapid
test
molecular
panel
antibiogram
clostridium
difficil
microbiolog
laboratori
integr
antibiot
stewardship
program
rapid
diagnost
technolog
potenti
decreas
time
appropri
therapi
improv
patient
care
implement
consult
clinician
clinic
microbiologist
antibiot
stewardship
team
antibiot
stewardship
team
help
guid
clinician
use
microbiolog
laboratori
interpret
antimicrobi
suscept
result
infect
di
clin
n
inappropri
excess
use
antibiot
contribut
emerg
antimicrobi
resist
advers
patient
outcom
includ
clostridium
difficil
infect
cdi
advers
drug
reaction
antimicrobialrel
patient
morbid
primari
goal
antimicrobi
stewardship
program
asp
optim
appropri
use
antimicrobi
improv
patient
outcom
reduc
advers
sequela
antimicrobi
use
decreas
emerg
spread
multidrugresist
infect
infecti
diseas
societi
america
societi
healthcar
epidemiolog
america
publish
guidelin
updat
assist
hospit
develop
implement
asp
activ
moreov
center
diseas
control
prevent
defin
seven
core
element
success
asp
joint
commiss
issu
regulatori
guidanc
program
guidelin
suggest
asp
activ
collabor
clinic
microbiolog
wake
forest
baptist
health
wfbh
tertiari
care
center
larg
cancer
center
transplant
servic
asp
activ
year
earliest
day
wfbh
clinic
microbiolog
laboratori
director
collabor
antimicrobi
stewardship
team
strong
partnership
asp
team
laboratori
extrem
fruit
result
mani
success
initi
improv
patient
care
addit
collabor
help
address
challeng
assimil
new
outpati
inpati
clinic
facil
rapidli
expand
health
care
system
challeng
includ
find
solut
integr
divers
exist
suscept
report
cascad
infecti
diseas
test
practic
antimicrobi
formulari
asp
newli
assimil
hospit
clinic
review
discuss
collabor
effort
undertaken
team
microbiolog
laboratori
illustr
experi
insight
success
challeng
encount
clinic
microbiolog
laboratori
essenti
part
asp
team
play
import
role
promot
appropri
antimicrobi
use
surveil
resist
pathogen
prevent
nosocomi
infect
convers
asp
team
extrem
import
entiti
advis
support
expand
clinician
outreach
microbiolog
laboratori
collabor
task
team
microbiolog
laboratori
includ
select
antimicrobi
suscept
test
panel
cascad
report
review
annual
antibiogram
evalu
new
methodolog
diagnosi
infecti
diseas
standard
antimicrobi
report
throughout
health
system
educ
commun
provid
provid
interpret
test
result
guid
appropri
use
antimicrobi
tabl
function
requir
close
collabor
team
clinic
microbiolog
laboratori
also
support
expertis
informat
hospit
leadership
provid
accept
follow
result
clinic
guidanc
accept
recommend
clinic
provid
larg
utmost
import
longterm
success
implement
program
intervent
team
often
facilit
accept
year
asp
staff
director
microbiolog
laboratori
review
current
antimicrobi
suscept
panel
correspond
set
test
antimicrobi
updat
panel
content
review
focus
addit
new
agent
modifi
antimicrobi
concentr
test
may
relev
specif
treatment
guidelin
ensur
laboratori
provid
clinic
relev
antimicrobi
suscept
result
program
routin
valid
implement
new
breakpoint
recommend
clinic
laboratori
standard
institut
clsi
addit
standard
rule
cascad
report
recommend
clsi
program
develop
addit
rule
antimicrobi
suscept
report
result
agent
hidden
hidden
suscept
often
agent
would
problemat
treat
select
infect
fluoroquinolon
invas
staphylococcu
aureu
facilit
final
goal
promot
use
right
agent
right
patient
hidden
suscept
result
must
approv
asp
member
call
consult
infecti
diseas
provid
microbiolog
laboratori
report
result
agent
electron
medic
record
report
algorithm
guid
provid
select
agent
among
report
usual
narrow
spectrum
enhanc
efficaci
consid
firstlin
therapi
organ
isol
report
rule
antimicrobi
suscept
result
describ
tabl
antibiogram
cumul
suscept
report
summari
local
rate
antimicrobi
suscept
organ
frequent
isol
clinic
specimen
antibiogram
serv
resourc
clinician
choos
empir
antibiot
therapi
track
chang
antibiogram
year
year
antibiogram
help
stewardship
program
identifi
emerg
resist
document
improv
suscept
rate
target
intervent
microbiolog
director
tradit
respons
prepar
valid
data
annual
antibiogram
accord
rule
describ
clsi
document
stewardship
personnel
includ
pharmacist
vest
interest
antibiogram
potenti
impact
antibiot
prescrib
reason
stewardship
pharmacist
often
work
microbiolog
laboratori
popul
suscept
valid
data
format
antibiogram
user
clinician
friendli
color
code
help
design
certain
antibiot
prefer
base
enhanc
suscept
institut
also
add
rel
antibiot
cost
inform
antibiogram
assist
clinician
point
antibiot
prescrib
modern
health
care
system
often
challeng
standard
antibiogram
serv
mani
stakehold
within
system
system
stakehold
includ
staff
work
differ
set
clinic
nurs
home
longterm
care
facil
commun
hospit
tertiari
care
medic
center
develop
antibiogram
serv
set
difficult
import
identifi
stewardship
staff
liaison
locat
provid
local
perspect
patient
popul
serv
antibiot
formulari
common
infect
encount
resist
concern
depend
structur
health
system
may
advantag
consolid
antibiogram
data
multipl
system
locat
especi
locat
common
characterist
eg
commun
hospit
clinic
geograph
area
consolid
antibiogram
data
also
improv
sampl
size
organ
infrequ
cultur
howev
barrier
develop
antibiogram
serv
multipl
locat
health
system
possibl
differ
locat
use
differ
assay
suscept
test
antibiot
test
differ
inconsist
formulari
work
microbiolog
system
stewardship
program
help
standard
align
process
make
consolid
antibiogram
feasibl
improv
consist
use
antibiot
throughout
system
antibiogram
limit
provid
singl
antibioticpathogen
pair
suscept
rate
adequaci
singl
agent
prescrib
empir
therapi
may
accept
clinic
practic
particularli
lifethreaten
infect
among
patient
risk
factor
antibioticresist
bacteria
addit
second
antibiot
improv
adequaci
empir
therapi
optim
combin
antibiot
direct
local
microbiolog
data
specif
microbiolog
stewardship
personnel
work
togeth
construct
combin
antibiogram
repres
institutionspecif
bacteri
pathogen
particular
diseas
ultim
determin
recommend
local
empir
treatment
guidelin
team
success
done
new
diagnost
techniqu
rapid
turnaround
time
pathogen
identif
accur
interpret
suscept
result
import
tool
patientcent
select
appropri
therapi
throughout
year
team
review
mani
new
laboratori
techniqu
methodolog
allow
rapid
identif
organ
mechan
resist
local
assess
clinic
use
test
patient
popul
import
factor
hospit
administr
decis
acquir
new
piec
equip
test
methodolog
relev
technolog
rapid
test
microbiolog
laboratori
evalu
implement
team
describ
next
doubt
matrixassist
laser
desorptionion
timeofflight
malditof
revolution
way
laboratori
identifi
microorgan
techniqu
identifi
unknown
organ
analyz
protein
present
separ
accord
mass
charg
time
take
protein
travel
inocul
site
detector
end
instrument
base
paramet
instrument
gener
protein
spectrum
compar
spectrum
includ
databas
instrument
main
advantag
malditof
speed
accuraci
identifi
microorgan
instrument
high
perform
characterist
robust
databas
identifi
common
organ
isol
clinic
specimen
overal
identif
achiev
hour
earlier
gram
posit
hour
earlier
gramneg
rod
yeast
compar
tradit
system
identif
furthermor
malditof
abl
accur
identifi
fastidi
difficult
identifi
organ
laboratori
previous
unabl
identifi
convent
identif
methodolog
report
unusu
organ
occasion
identifi
malditof
unintend
consequ
clinician
may
unfamiliar
organ
report
potenti
pathogen
potenti
lead
unnecessari
antimicrobi
treatment
consult
asp
team
recommend
assess
report
languag
medic
record
clinician
might
respond
staphylococcu
epidermidi
result
compar
coagulaseneg
staphylococcu
report
studi
shown
rapid
identif
organ
malditof
improv
time
appropri
antibiot
treatment
associ
asp
collabor
laboratori
wfbh
implement
malditof
technolog
team
fundament
educ
provid
use
earli
identif
result
implement
empir
therapi
provid
reliabl
local
antibiogram
report
overal
institut
implement
malditof
clearli
improv
turnaround
time
identif
organ
although
malditof
provid
suscept
test
mani
organ
predict
suscept
case
rapid
identif
result
appropri
patient
manag
mani
year
molecular
detect
singl
organ
methicillinresist
aureu
shown
clinic
use
singledrugresist
organ
last
decad
howev
dramat
increas
develop
multiplex
molecular
assay
design
detect
multipl
pathogen
associ
infecti
syndrom
rather
one
specif
organ
multiplex
polymeras
chain
reaction
pcr
assay
usual
offer
panel
simultan
detect
singl
specimen
pathogen
commonli
associ
infecti
syndrom
bloodstream
meningitisenceph
respiratori
gastrointestin
infect
implement
rapid
method
must
critic
evalu
consid
test
volum
patient
popul
avail
laboratori
personnel
clinic
support
ensur
diagnost
technolog
select
appropri
clinic
servic
particular
institut
overus
inappropri
use
rapid
test
may
increas
cost
without
provid
expect
improv
diagnosi
patient
care
addit
mani
multiplex
test
reimburs
thirdparti
payer
outpati
set
lead
seriou
econom
consequ
health
care
system
patient
asp
affili
clinic
laboratori
valu
determin
whether
test
paramet
sensit
specif
posit
neg
predict
use
implement
addit
help
develop
protocol
identifi
appropri
patient
test
subsequ
test
interpret
tabl
describ
select
molecular
panel
implement
experi
use
tabl
also
show
descript
requir
order
molecular
panel
one
import
factor
influenc
treatment
outcom
patient
bloodstream
infect
appropri
earli
antimicrobi
therapi
addit
prompt
initi
effect
therapi
avoid
unnecessari
exposur
broadspectrum
antibiot
import
limit
advers
event
prevent
emerg
antibiot
resist
main
advantag
rapid
blood
cultur
identif
panel
identifi
organ
hour
blood
cultur
signal
posit
compar
hour
use
tradit
methodolog
furthermor
panel
also
identifi
genet
element
resist
mechan
make
use
select
antibiot
therapi
multidrugresist
organ
wfbh
implement
biofir
filmarray
blood
cultur
identif
panel
biomerieux
durham
nc
current
resourc
alloc
use
panel
blood
cultur
optim
costeffect
target
patient
greatest
risk
elect
use
test
routin
blood
cultur
patient
locat
intens
care
oncolog
unit
studi
impact
panel
implement
patient
noncontamin
gramposit
bacteremia
found
improv
metric
shown
fig
improv
attribut
shorten
time
organ
identif
abil
detect
resist
median
time
identif
improv
hour
implement
panel
also
improv
stewardship
metric
patient
blood
cultur
posit
like
contamin
patient
blood
cultur
contamin
studi
demonstr
reduct
day
antibiot
therapi
shorter
length
hospit
stay
fewer
test
vancomycin
level
optim
use
rapid
diagnost
test
includ
multiplex
molecular
blood
cultur
panel
best
done
conjunct
dedic
stewardship
personnel
provid
antibiot
guidanc
time
result
avail
wfbh
team
microbiolog
staff
collabor
evalu
approach
commun
posit
blood
cultur
panel
result
instead
report
posit
cultur
nurs
result
report
directli
stewardship
pharmacist
relay
result
respons
provid
along
antibiot
guidanc
method
commun
posit
cultur
improv
stewardship
metric
beyond
rapid
panel
could
achiev
alon
see
fig
hospit
howev
may
struggl
maintain
model
report
hour
day
day
week
initi
implement
molecular
blood
cultur
test
team
report
later
elect
report
result
use
inbasket
function
within
electron
medic
record
conjunct
tradit
report
nurs
inpati
acut
care
pharmacist
receiv
inbasket
result
instead
dedic
stewardship
pharmacist
passiv
report
panel
result
achiev
improv
stewardship
metric
time
optim
therapi
time
deescal
regress
back
level
close
tradit
method
report
nurs
data
shown
experi
highlight
need
dedic
stewardship
personnel
along
rapid
diagnost
achiev
best
outcom
respiratori
tract
infect
one
common
caus
morbid
mortal
age
group
clinic
present
differ
organ
often
similar
furthermor
larg
portion
lower
respiratori
tract
infect
caus
virus
mycoplasma
chlamydophila
multiplex
pcr
respiratori
virus
difficulttocultur
bacteria
includ
pertussi
frequent
use
panel
test
respiratori
infect
test
respiratori
virus
influenza
controversi
mani
argu
detect
virus
treatment
may
clinic
import
other
state
identifi
noninfluenza
respiratori
virus
benefici
decreas
addit
test
provid
valuabl
inform
epidemiolog
infect
prevent
purpos
limit
use
antibiot
wfbh
first
respiratori
viral
panel
rvp
multiplex
pcr
respiratori
virus
implement
around
time
influenza
pandem
initi
mostli
use
diagnosi
influenza
quickli
becam
use
tool
assess
patient
respiratori
infect
current
laboratori
use
multiplex
pcr
assay
includ
respiratori
virus
four
bacteri
pathogen
begin
microbiolog
stewardship
staff
posit
rvp
use
immunocompromis
patient
moder
sever
respiratori
infect
need
hospit
test
could
order
without
preauthor
restrict
time
volum
order
rvp
substanti
increas
maximum
volum
observ
month
influenza
activ
high
cost
test
escal
rvp
volum
underscor
import
diagnost
stewardship
prudent
use
test
addit
test
perform
depend
collect
proper
nasopharyng
swab
physician
nurs
train
procedur
evalu
whether
rvp
test
improv
stewardship
metric
wfbh
microbiolog
stewardship
staff
collabor
determin
impact
rvp
test
use
antibiot
respiratori
infect
conduct
prospect
studi
nonimmunocompromis
inpati
test
rvp
measur
antibiot
use
associ
respiratori
infect
result
studi
show
provid
like
discontinu
deescal
antibiot
rvp
posit
tabl
hospit
length
stay
attribut
mortal
chang
microbiolog
stewardship
team
need
balanc
improv
stewardship
metric
associ
test
cost
high
volum
burden
laboratori
thu
although
escal
cost
rvp
test
concern
may
offset
reduc
antibiot
expens
improv
use
wfbh
stewardship
team
current
implement
diagnost
stewardship
rvp
decreas
volum
improv
select
patient
test
infecti
diarrhea
caus
bacteri
viral
parasit
pathogen
remain
signific
health
care
burden
worldwid
although
gastrointestin
infect
sever
immunosuppress
pediatr
elderli
patient
infect
selflimit
need
antimicrobi
treatment
convent
test
gastrointestin
pathogen
lack
sensit
take
day
result
becom
avail
gastrointestin
panel
result
avail
hour
detect
import
bacteri
parasit
viral
pathogen
caus
diarrhea
unit
state
result
avail
day
sampl
submit
patient
still
symptomat
may
lead
antibiot
treatment
reason
wfbh
comment
includ
gastrointestin
panel
result
recommend
prevent
misus
antibiot
question
whether
treatment
necessari
posit
test
enteropathogen
escherichia
coli
refer
stewardship
pager
addit
improv
diagnost
accuraci
assay
help
us
quickli
detect
control
noroviru
outbreak
well
salmonella
spp
outbreak
involv
multipl
counti
region
panel
biofir
rapidli
detect
pathogen
commonli
associ
syndrom
infect
howev
publish
evalu
perform
panel
show
fals
posit
particularli
streptococcu
pneumonia
falseposit
result
may
lead
unnecessari
therapi
importantli
falseposit
result
may
delay
halt
pursuit
true
diagnosi
addit
provid
awar
sensit
detect
differ
pathogen
includ
panel
vari
consider
reason
wfbh
suspect
herp
simplex
viru
hsv
infect
inhospit
mortal
n
abbrevi
dot
day
antibiot
therapi
virus
detect
rvp
includ
influenza
respiratori
syncyti
viru
metapneumoviru
rhinoenteroviru
coronaviru
particularli
neonat
recommend
order
standalon
hsv
pcr
test
cerebrospin
fluid
higher
sensit
hsv
target
includ
meningitisenceph
panel
mep
main
benefit
mep
rapid
result
could
help
select
appropri
therapi
priorit
resourc
use
addit
use
determin
whether
droplet
isol
secondari
chemoprophylaxi
requir
neisseria
mening
potenti
falseposit
result
possibl
detect
latent
reactiv
virus
result
mep
must
care
assess
wfbh
mep
order
routin
process
specimen
less
wbcdl
unless
approv
consult
infecti
diseas
team
member
posit
result
bacteri
pathogen
correl
cultur
confirm
diagnosi
diagnost
stewardship
refer
appropri
use
laboratori
test
guid
patient
manag
treatment
real
time
goal
enhanc
clinic
outcom
limit
spread
antimicrobi
resist
goal
asp
microbiolog
laboratori
intertwin
inasmuch
laboratori
result
direct
antibiot
decis
make
phase
diagnost
effort
preanalyt
phase
analyt
phase
postanalyt
phase
critic
element
test
process
significantli
impact
diagnost
accuraci
antimicrobi
prescrib
respons
test
result
overus
unnecessari
test
increas
likelihood
falseposit
test
result
may
lead
erron
diagnos
inappropri
antibiot
usag
therefor
asp
microbiolog
laboratori
must
collabor
design
diagnost
stewardship
process
aim
achiev
collect
goal
wfbh
asp
microbiolog
laboratori
identifi
area
could
benefit
diagnost
stewardship
one
success
initi
involv
test
cdi
enzym
immunoassay
eia
detect
presenc
toxin
initi
commonli
use
test
diagnosi
cdi
low
sensit
result
falseneg
result
wfbh
convert
nucleic
acid
amplif
test
pcr
diagnosi
cdi
observ
twofold
increas
number
diagnos
grow
concern
regard
overdiagnosi
cdi
led
us
evalu
cdi
diagnos
wfbh
clinic
specimen
submit
pcr
test
test
concurr
eia
simultan
test
c
difficil
antigen
toxin
member
asp
perform
chart
review
patient
made
assess
likelihood
cdi
blind
eia
result
analysi
show
eia
better
predictor
cdi
confirm
suspicion
overdiagnosi
use
pcr
alon
evalu
also
identifi
common
reason
diarrhea
led
unnecessari
cdi
test
mani
iatrogen
sever
initi
improv
patient
select
test
pretest
likelihood
cdi
success
includ
electron
medic
record
best
practic
advisori
algorithm
nurs
provid
educ
support
data
assess
convert
eia
test
april
ahead
guidelin
european
american
societi
recommend
highsensit
eia
assay
first
step
follow
highspecif
toxin
test
includ
report
eia
result
ad
explanatori
comment
tabl
clinic
decis
support
pcr
test
still
avail
wfbh
requir
author
member
asp
chang
assay
pcr
test
frequenc
declin
rate
intern
classif
code
cdi
declin
rate
nhsn
c
difficil
labid
event
rate
patient
day
declin
number
patient
treat
oral
vancomycin
declin
postimplent
audit
show
increas
cdi
morbid
mortal
miss
case
inpati
cdi
year
identifi
certain
antimicrobi
suscept
result
misinterpret
clinician
misinterpret
lead
addit
unnecessari
test
eg
special
mic
use
altern
antibiot
team
microbiolog
laboratori
develop
support
guidanc
incorpor
within
test
result
overcom
issu
exampl
comment
includ
test
result
list
tabl
furthermor
special
extrasuscept
test
must
approv
member
team
rapid
methodolog
particularli
multiplex
molecular
panel
repres
paradigm
shift
diagnosi
clinic
infecti
diseas
main
benefit
rapid
assay
potenti
improv
patient
care
particularli
associ
support
local
implement
rapid
method
prepar
antibiogram
interpret
antimicrobi
suscept
test
done
partnership
pharmaci
clinician
vers
ensur
appropri
test
use
clear
understand
test
characterist
result
interpret
opportun
expert
opinion
influenc
antimicrobi
treatment
author
noth
disclos
tabl
exampl
comment
includ
antimicrobi
suscept
test
report
h
influenza
consid
suscept
ceftriaxon
meropenem
even
blactamas
posit
h
influenza
haemophilu
parainfluenza
respiratori
specimen
h
influenza
may
produc
blactamas
caus
resist
penicillin
ampicillin
amoxicillin
howev
h
influenza
gener
suscept
amoxicillinclavulan
cefuroxim
cefpodoxim
cefdinir
ceftriaxon
azithromycin
even
blactamas
posit
group
b
streptococcu
vaginalrect
swab
screen
pregnant
women
group
b
streptococci
univers
suscept
ampicillin
penicillin
cefazolin
test
necessari
clindamycin
report
suscept
result
confirm
test
organ
consid
suscept
clindamycin
escherichia
coli
klebsiella
pneumonia
proteu
mirabili
cleancatch
urin
cefazolin
breakpoint
urin
appli
treatment
uncompl
urinari
tract
infect
cefazolin
suscept
predict
suscept
oral
cephalosporin
cephalexin
cefuroxim
cefpodoxim
cefdinir
cephalexin
costeffect
qid
dose
normal
renal
function
less
conveni
oral
cephalosporin
dose
bid
isol
resist
cefazolin
suscept
ceftriaxon
may
suscept
cefpodoxim
carbapenemresist
enterobacteriacea
base
addit
test
follow
comment
ad
carbapenamaseproduc
organ
consult
team
treatment
recommend
